Overview
Delpharm Poznań is a leading CDMO specializing in the development and manufacturing of pharmaceuticals for the pharmaceutical industry. The company offers expertise in solid, sterile, semi-solid, and liquid forms, with a particular focus on nasal spray production, providing flexible manufacturing capabilities and diverse packaging options. Delpharm operates multiple production sites in Europe and North America, ensuring high-quality and compliant therapeutic solutions.
Financials
Financial insight
- Possible Estonian CIT: Equity includes Art. 28d line items, but all amounts are 0 — this may be an accounting template or the first year of the regime.
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
Delpharm strengthens its sterile vial capabilities
Delpharm strengthens its capabilities in sterile vials
Delpharm strengthens its sterile vial capabilities
Delpharm continues to make strategic investments in its sites specialising in the manufacture of sterile liquid and powder vials.
Delpharm strengthens its sterile vial capabilities
Highly specialized knowledge for your projects concerning sterile products in bottles
Industry
Bank accounts
Registered as a VAT taxpayer on 1994-01-01. Active
12 1030 1508 0000 0005 0022 3227- 62 1030 1508 0000 0005 0022 3006
- 68 1030 1508 0000 0005 0022 3189
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Nov 23, 2021 | Commercial Companies Code notice | |
| Nov 4, 2021 | Demerger announced | |
| Dec 1, 2014 | Commercial Companies Code notice |
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Aug 3, 2020 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $18,166 | Zarządca Rozliczeń S.A. | |
| Aug 3, 2020 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $15,285 | Zarządca Rozliczeń S.A. |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | Waste generation | Active |
Authorized Representatives
Manner of representation
To make declarations of will on behalf of the company and sign documents on its behalf, joint action by two members of the management board or one member of the management board jointly with a commercial proxy is required.
Supervisory board
Ownership
| Owner | Share value | Stake |
|---|---|---|
Delpharm Industrie Sas | $39,949,524.58 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Sebastien Gabriel Marie Aguettant (56)  | Wspólnik posiadający 100% udziałów w financière sebastien aguettant (société civile), będącej większościowym akcjonariuszem (powyżej 25% akcji) w delpharm sas (société par actions simplifiée), będącej większościowym akcjonariuszem (powyżej 25% akcji) w delpharm industrie sas (société par actions simplifiée), będącej 100% akcjonariuszem w delpharm poznań spółka akcyjna. |
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| Adamed PharmaS.A. | $541,927,181.76 | adamed.com.pl | |
| Aflofarm Farmacja Polskasp. z o.o. | $302,019,142.07 | aflofarm.pl | |
| Anpharm Przedsiębiorstwo FarmaceutyczneS.A. | $111,469,394.21 | anpharm.pl | |
| Przedsiębiorstwo Produkcji Farmaceutycznej Hasco - LekS.A. | $119,621,017.71 | hasco-lek.pl | |
| Tarchomińskie Zakłady Farmaceutyczne PolfaS.A. | $102,988,448.02 | polfa-tarchomin.com.pl | |
| ICN Polfa RzeszówS.A. | $85,044,250.03 | icnpolfa.pl | |
| PolfarmexS.A. | $73,543,379.32 | polfarmex.pl | |
| Wrocławskie Zakłady Zielarskie HerbapolS.A. | $46,537,868.51 | herbapol.pl | |
| Phytopharm KlękaS.A. | $46,154,888.31 | phytopharm.pl | |
| Instytut Biotechnologii Surowic i Szczepionek Biomed - Skrót Firmy Ibss BiomedS.A. | $37,103,878.54 | biomed.pl |
Change history
| Date | Event |
|---|---|
| 2022-06-30 | Name change (Glaxosmithkline Pharmaceuticals → Delpharm Poznań) |
| 2001-05-28 | Name change (Glaxo Wellcome → Glaxosmithkline Pharmaceuticals) |
| 2001-05-25 | Entered in the register |
FAQ
Last updated: 2026-03-31